Arctiin

Other Names

(3R,4R)-4-[(3,4-Dimethoxyphenyl)methyl]-3-[[4-(beta-D-glucopyranosyloxy)-3-methoxyphenyl]methyl]dihydro-2(3H)-furanone2(3H)-Furanone, 4-[(3,4-dimethoxyphenyl)methyl]-3-[[4-(beta-D-glucopyranosyloxy)-3-methoxyphenyl]methyl]dihydro-, (3R,4R)-2(3H)-Furanone, 4-[(3,4-dimethoxyphenyl)methyl]-3-[[4-(beta-D-glucopyranosyloxy)-3-methoxyphenyl]methyl]dihydro-, (3R-trans)-Arctigenin 4-glucosideArctigenin 4-O-beta-D-glucopyranosideArctigenin-4'-O-glucosideArctigenin-O-beta-D-glucopyranosideArctiiArctii FructusArctinFructus ArctiiNSC 315527

Synopsis

Arctiin: A Comprehensive Encyclopedic Reference

1. Identity: Botanical and Chemical Classification

1.1 Names and Taxonomy

Arctiin (also spelled arctin) is a naturally occurring phenylpropanoid lignan glycoside. Arctiin is a lignan found in many plants of the family Asteraceae, particularly the greater burdock (Arctium lappa) and Centaurea imperialis, and in Trachelospermum asiaticum, Saussurea heteromalla, and Forsythia viridissima. It is the glucoside of arctigenin.

Arctiin has the empirical formula C₂₇H₃₄O₁₁, a CAS number of 20362-31-6, and a molecular weight of 534.55. Its synonyms include Arctigenin-4-Glucoside and NSC 315527. The formal IUPAC-derived systematic name of the compound, as listed in chemical databases, is (3R,4R)-4-[(3,4-dimethoxyphenyl)methyl]-3-[[4-(beta-D-glucopyranosyloxy)-3-methoxyphenyl]methyl]dihydro-2(3H)-furanone.

Arctiin is classified as both a glycoside and a lignan. Its aglycone — the form produced after removal of the glucose moiety — is arctigenin, which has the molecular formula C₂₁H₂₄O₆. Arctigenin's systematic name describes a compound with a dibenzylbutyrolactone skeleton.

1.2 Primary Botanical Source

Arctium lappa, also known as burdock, is widely consumed in East Asia, Europe, and America to promote well-being for hundreds of years. The plant belongs to the Asteraceae family and is a shrub that grows to roughly 1 m in height, with roots that can extend to 45–50 cm in depth and 3–6 cm in diameter. Arctium lappa L. is also called Niubang in Chinese, gobo in Japanese, burdock in English, and repejnik in Russian, and this plant has been cultivated in China, Japan, and Korea as a root vegetable.

Fruits and seeds of A. lappa contain the highest levels of arctigenin and arctiin, while other parts such as flower, leaves, stem, and roots contain lower levels. A burdock fruit contains approximately 7% of arctiin, which is classified as a lignan glycoside, and approximately 0.6% of arctigenin, which is the aglycone of arctiin. The seeds, more commonly used in TCM, contain higher levels of arctigenin than the root.

In the family Asteraceae, Centaurea is a genus that includes many arctigenin- and arctiin-containing plants, although the arctigenin and arctiin contents are lower than that in A. lappa. Additional sources outside the Asteraceae family include Forsythia viridissima and Trachelospermum asiaticum.

1.3 Distribution within the Plant

The main compounds of burdock extracts are caffeoylquinic acid derivatives, lignans (mainly arctiin), and various flavonoids. The occurrence of some phenolic acids (caffeic acid, chlorogenic acid, and cynarin) in burdock seeds; arctiin, luteolin, and quercetin rhamnoside in burdock roots has been documented. Arctiin and arctigenin have been isolated and identified in the leaves of burdock (Arctium lappa L.) as well. Beyond arctiin and arctigenin, the lignan complement of Arctium lappa includes neoarctin and mataresinol.

1.4 Common Forms and Preparations

Arctiin occurs commercially in several forms. It is available as a purified reference standard (≥95–98% purity by LC/MS-ELSD) for research purposes. As a pure compound, arctiin is a crystalline solid with solubility in DMF and DMSO at 30 mg/mL, in DMSO:PBS (1:1) at 0.5 mg/mL, and in ethanol at 2 mg/mL. In dietary supplement contexts, it is delivered primarily through standardized burdock fruit (Arctii Fructus) extracts. Some clinical research has utilized a product containing 1.2% burdock fruit extract standardized to 0.25% arctiin. Traditional preparations include dried and processed burdock fruit, roots, and leaves used as decoctions or powdered herbs.

2. Traditional and Historical Use

2.1 Traditional Chinese Medicine

Arctii Fructus (named Niubangzi in Chinese), the fruit (achene) of Arctium lappa L., has the characteristics of pungent, bitter, with the character of cold in the Pharmacopoeia of the People's Republic of China. Arctii Fructus as a top-class herb was first recorded in Mingyi Bielu in the late Han Dynasty, with a history of nearly 1800 years. It was traditionally used to dispel wind-heat, ventilate the lung qi to promote eruption, remove toxic substances, and relieve a sore throat.

In Chinese traditional medicine, Arctium lappa (mainly roots, and to a lesser extent, seeds and leaves) is an important herbal medicinal preparation. It is commonly used for alleviating symptoms of inflammatory disorders, such as anemopyretic cold, cough, measles, urticaria, and furuncle. Burdock seeds, called niubangzi in China, have been extensively used in traditional Chinese medicine as anti-inflammatory, detoxifying, and diuretic agents for relieving sore throat, decreasing swelling, promoting urination, and removing toxic substances.

As a component in the Chinese pharmacopoeia, arctiin exerts traditional therapeutic actions described as designed to "ease the throat, dissipate nodules, remove toxic materials, expel wind and heat." As a traditional medicine, arctiin has been widely used in Asia, Europe, and North America for centuries.

2.2 Japanese and Korean Traditions

Historically, Japan used burdock roots for food for nearly 1,000 years, as well as using roots, leaves, and seeds for medicinal purposes. Roots are still widely eaten as a vegetable in Japan, Korea, and Taiwan and to a lesser extent in Italy, Portugal, and Brazil.

2.3 European Traditions

Arctium lappa roots have been used for hundreds of years as traditional medicines by multiple European, Asian, and North American cultures for a variety of purposes including to improve the immune system and enhance metabolism, as well as for their anti-inflammatory and anticancer effects. Europeans also used the plant for both food and medicine. In European traditions, Arctium lappa is also applied to treat various skin disorders including eczema and acne.

The European monograph tradition for burdock root is well established. The ESCOP herbal monograph selects and summarizes scientific studies and textbooks regarding efficacy, dosage, and safety to support the therapeutic uses of burdock root, which consists of dried, whole, or cut roots of Arctium lappa L., A. minus (Hill) Bernh., A. tomentosum Mill., and hybrids or mixtures thereof. The therapeutic indications addressed in that monograph include seborrhoeic skin, eczema, furuncles, acne, psoriasis, and use as an adjuvant in minor urinary tract complaints, by increasing the amount of urine to achieve flushing of the urinary tract. The European Medicines Agency (EMA) recommends the roots of Arctium lappa as adjunct therapy for seborrheic skin conditions and urinary tract infections.

2.4 North American Indigenous Use

Pilgrims introduced the burdock plant to North America for similar food and medicinal uses. After burdock spread in North America, some Native communities incorporated the newcomer into local plant knowledge. Ethnobotanical records compiled by Daniel E. Moerman note Iroquois uses of burdock preparations, a reminder that plant traditions often changed as new species appeared along trade routes and settlement edges.

2.5 Middle Eastern and Other Traditions

Arctium lappa is among commonly used traditional medicines in Iraq for treatment of diseases related to cancer or that may lead to cancer, such as skin diseases, blood-related diseases, inflammatory diseases, immune disorders, and infectious diseases.

3. Key Constituents and Chemical Context

3.1 Phytochemical Profile of Arctium lappa

Lignans are the most characteristic phytoconstituents of Arctium lappa. To date, more than 200 compounds have been isolated and identified from Arctii Fructus (burdock fruit). It contains lignans, phenolic acids and fatty acids, terpenoids, volatile oils, and others. Beyond arctiin and arctigenin, the plant contains mucilage, tannins, polyphenols such as chlorogenic acid and caffeoylquinic acids. Burdock root also contains inulin, a soluble plant fiber found in chicory, dandelion root, and Jerusalem artichoke.

3.2 Arctiin as a Prodrug: The Relationship to Arctigenin

A critical chemical distinction is that arctiin itself serves largely as a prodrug or storage form. Arctigenin is an active ingredient in burdock, albeit at low quantities or mostly in the form of arctiin (arctigenin-4-glucoside). The biological conversion of arctiin to its active metabolite is mediated by intestinal microflora. Arctiin is metabolized by human intestinal bacteria into various bioactive metabolites including arctigenin and enterolactone, which respectively exhibit growth inhibitory and growth promoting activity in MCF-7 breast cancer cells at 10 µM.

Human intestinal microflora was reported to convert arctiin, the lignan compound with the highest content in the dried fruits of Arctium lappa, into multiple demethylated and oxidized products. Bacterium strain ARC-2 was reported to be able to convert the metabolite arctigenin to seven different metabolites, including three monodesmethylarctigenins, three didesmethylarctigenins, and dihydroxyenterolactone.

3.3 Pharmacokinetics and Metabolism

Pharmacokinetic studies have demonstrated extensive glucuronidation and hydrolysis of arctigenin in liver, intestine, and plasma, which might hinder its in vivo and clinical efficacy after oral administration. Three major metabolites — arctigenic acid (AA), arctigenin-4′-O-glucuronide (AG), and 4-O-demethyl-arctigenin (DAR) — were identified in rat plasma as early as 30 minutes after oral administration, with concentrations higher than arctigenin itself, suggesting rapid absorption and extensive first-pass metabolism.

Pharmacokinetic studies proposed that the extensive first-pass metabolism of arctigenin after oral administration would hinder its in vivo and clinical efficacy. The tissue levels of arctigenin peaked at 30 minutes following oral administration of 70 mg/kg in rats and were rapidly removed within 4 hours, with maximum arctigenin levels reported in the spleens, followed by the liver and other organs.

Regarding excretion, arctiin was eliminated at a rate of 19.84% in urine and 1.80% in feces. Enterolactone, the primary metabolite, was eliminated in feces at a rate of 35.80%. Metabolic species differences are significant: according to Li et al. (2017), about 62%, 3.7%, 15.7%, and 25.9% of the arctigenin substance remained after being exposed to human, monkey, rat, and dog liver microsomes for a duration of 90 minutes.

3.4 Relationship to Mammalian Lignans

Although most lignans are derived from plants, many of them are metabolized by mammalian gut microbiota. The conversion of plant lignans such as arctiin and arctigenin to the mammalian lignans enterodiol and enterolactone follows a well-characterized pathway involving microbial demethylation, dehydroxylation, and oxidation steps. Research published in Chemical & Pharmaceutical Bulletin has documented the transformation of arctiin to estrogenic and antiestrogenic substances by human intestinal bacteria.

4. Mechanisms of Action

4.1 Anti-Inflammatory Mechanisms

The most extensively characterized mechanism of arctiin is its inhibition of inflammatory signaling cascades. Arctiin dose-dependently decreases the production of nitric oxide and proinflammatory cytokines such as IL-1β, IL-6, TNF-α, and PGE₂. The expression of co-stimulatory molecules such as B7-1 and B7-2 was also inhibited by arctiin. Furthermore, the activation of the nuclear transcription factor NF-κB in macrophages was inhibited by arctiin.

Results from macrophage studies demonstrated that arctiin largely inhibited the excessive production of inflammatory mediators such as NO, PGE₂, TNF-α, IL-1β, and IL-6, as well as suppression of COX-2, through the inhibition of the NF-κB translocation pathway.

Additional inflammatory pathway involvement has been identified in skin inflammation models. Arctiin was docked into the binding pocket of TLR4, and studies showed it modulates the TLR4/MyD88/NF-κB and NLRP3/Caspase-1/GSDMD signaling pathways in keratinocytes. Arctiin has been shown to protect mice from lipopolysaccharide (LPS)-mediated acute lung injury via inactivation of PI3K/AKT signaling.

Arctigenin, the active aglycone metabolite, exhibits potent anti-inflammatory activities by inhibiting inducible nitric oxide synthase (iNOS) via modulation of several cytokines. Arctiin plays an important role in the process of inflammation by preventing the release of nitric oxide, prostaglandin E₂, TNF-α (tumor necrosis factor-α), interleukin (IL)-1β, and IL-6.

4.2 Anticancer Mechanisms

Arctiin's antiproliferative effects operate through multiple molecular targets. Arctiin induces growth inhibition and dephosphorylates the tumor-suppressor retinoblastoma protein. The growth inhibition caused by arctiin is associated with the down-regulation of cyclin D1 protein expression. Furthermore, the arctiin-induced suppression of cyclin D1 protein expression occurs in various types of human tumor cells, including osteosarcoma, lung, colorectal, cervical and breast cancer, melanoma, transformed renal cells, and prostate cancer.

Cyclin D1 suppression is mechanistically central: depletion of the cyclin D1 protein using small interfering RNA rendered human breast cancer MCF-7 cells insensitive to the growth inhibitory effects of arctiin, implicating cyclin D1 as a key mediator of its antiproliferative activity.

In rodent cancer models, treating experimental rats with arctiin significantly reduced the expression of both TGF-β1 and STAT3. This deactivation of STAT-3 can suppress cancer-related inflammation and reduce the immune-suppressive environment of tumors, leading to the activation of antitumor immunity and the enhancement of cytotoxic T-cell effector functions. Arctiin has been reported to inhibit STAT3 phosphorylation at the tyrosine 705 residue and has shown potential in treating human multiple myeloma cells.

In an experimental hepatocellular carcinoma rat model, arctiin was found to significantly decrease the expression of HIF-1α, PKC, ERK, β-catenin, and SMAD4.

4.3 Adiponectin Receptor Agonism

Arctiin and arctigenin have been found to act as agonists of adiponectin receptor 1. This mechanism has potential relevance to metabolic and anti-inflammatory effects, as adiponectin receptor signaling is linked to glucose regulation and lipid homeostasis.

4.4 Antioxidant Mechanisms

Arctiin demonstrates antioxidant properties through several mechanisms. The activation of the Nrf2/HO-1 (nuclear factor erythroid 2-related factor 2 / heme oxygenase-1) signaling axis has been documented in the context of viral inflammation, where arctiin suppresses oxidative injury. Arctigenin, arctiin's aglycone, shows antioxidant, anti-inflammatory, and antiviral properties.

4.5 AMPK Pathway Modulation

Arctium lappa exerts antidiabetic effects via multi-layered mechanisms, including AMPK activation, insulin signaling modulation, and increased GLUT4 translocation. Key bioactives, including arctigenin, arctiin, and inulin, collectively improve insulin sensitivity and lipid metabolism. ARC-mediated activation of autophagy was postulated to be intermediated through the stimulation of AMP-activated protein kinase (AMPK) and mTOR signaling pathways.

5. Scientific Evidence by Area of Use

5.1 Inflammation

Preclinical evidence (in vitro / animal): The anti-inflammatory evidence for arctiin is substantial at the preclinical level. Arctiin, isolated from Forsythia suspensa, has been reported to have anti-inflammatory, anti-oxidant, antibacterial, and antiviral effects in vitro. Multiple in vitro studies using LPS-stimulated macrophage cell lines (RAW264.7) have confirmed dose-dependent suppression of NO, PGE₂, IL-1β, IL-6, and TNF-α via NF-κB pathway inhibition.

Clinical evidence: The alleviating effects of Arctii Fructus on chronic inflammation and ageing have been demonstrated by clinical studies. One referenced human study involved burdock root tea in patients with knee osteoarthritis: drinking Arctium lappa root tea reduced inflammation and oxidative stress in 36 patients with knee osteoarthritis. This clinical evidence is preliminary and limited in scope — single small studies rather than large, pre-registered randomized controlled trials.

Strength of evidence: Preclinical evidence is robust and mechanistically consistent across multiple study types. Human clinical evidence is limited, and the published review in Acta Pharmacologica Sinica concludes that arctigenin was reported as the most potent bioactive component in the majority of studies, though the clinical evidence base needs further expansion.

5.2 Cancer

Preclinical evidence (in vitro / animal): Lignans, especially arctigenin and arctiin, have shown extensive pharmacological effects including anti-cancer activities. Studies in cell lines have documented growth inhibition across numerous tumor types. In an animal model of Ehrlich solid carcinoma, some rats received a daily oral dose of 30 mg/kg of arctiin for three weeks, with the results showing that tumor size and weight were effectively reduced, leading to an increase in the average survival time of rats and an improvement in muscle structure. In an experimental hepatocellular carcinoma rat model dosed at 30 mg/kg twice a week for 16 weeks, arctiin was found to potentially increase the survival rate of rats, achieved through a reduction in serum AFP levels and hepatic nodules. Arctiin was also found to inhibit the formation of fibrotic tissues and necrotic nodules in HCC rats.

A significant mechanism for cancer utility involves selective toxicity under nutrient-deprived conditions: arctigenin has been identified as an antitumor agent having the ability to eliminate the tolerance of cancer cells to nutrient starvation.

A study investigating the effects of arctiin on chemically induced carcinogenesis documented effects of arctiin on PhIP-induced mammary, colon, and pancreatic carcinogenesis in female Sprague-Dawley rats and MeIQx-induced hepatocarcinogenesis in male F344 rats, published in Cancer Letters (2000).

Human clinical evidence: Arctiin and arctigenin have shown anticancer effects in animal research. A registered human trial (ClinicalTrials.gov NCT03703388) has been designed to evaluate the safety and uptake rate of pure arctigenin in humans, which may be potentially used in the future for prostate cancer prevention. A human study measuring the uptake of arctigenin into blood after consumption of the herb extract containing arctigenin found no toxicity.

Strength of evidence: The anticancer evidence for arctiin/arctigenin is currently limited to in vitro models, animal models, and one Phase I-type human safety and pharmacokinetics study. No completed randomized controlled trials in human cancer patients have been published. Evidence is promising but preliminary.

5.3 Antiviral Activity

Preclinical evidence: Arctiin has also shown antiviral activity against influenza A when used alone or in combination with oseltamivir. Arctiin was found to increase virus-specific antibodies against influenza A (H1N1) virus. A study on avian influenza H9N2 investigated the effect of arctiin on H9N2 virus infection and the underlying molecular mechanism in vitro. The antiviral effect against H9N2 virus was determined by plaque reduction assay (PRA) and progeny virus reduction assay. Specifically, a published study investigated the therapeutic effect of arctiin and arctigenin in immunocompetent and immunocompromised mice infected with influenza A virus.

Strength of evidence: Antiviral evidence is primarily in vitro and in small animal models. No large-scale randomized controlled human trials on arctiin as an antiviral agent have been published. Evidence remains early-phase.

5.4 Diabetes and Metabolic Effects

Preclinical evidence: A study using a rat model shows that arctiin possesses anti-diabetic activity and might serve as an inhibitor of diabetic retinopathy. The primary mechanisms proposed include AMPK activation, enhanced GLUT4 translocation, and modulation of insulin signaling pathways, as documented in animal studies.

Clinical evidence and limitations: Preclinical studies confirm these effects in animal models, while limited clinical data in non-diabetic cohorts focus on systemic inflammation. This highlights a significant gap in randomized controlled trials targeting glycemic control in diabetic populations. While Arctium lappa shows promise as a potential metabolic regulator, this evidence is currently derived primarily from in vitro and animal models. Systematic clinical trials are urgently required to establish glycemic efficacy in humans, validate its therapeutic potential, and determine the optimal dosage and safety profile.

Strength of evidence: Weak at the human level. Predominantly animal and in vitro data. The antidiabetic potential is mechanistically plausible but unconfirmed in controlled human studies.

5.5 Neuroprotection

Preclinical evidence: Arctigenin was shown to exert a neuroprotective effect in an animal model of ischemic stroke through its anti-inflammatory property. It was reported that arctigenin can protect against memory impairment and decrease beta-amyloid formation and senile plaques in Alzheimer's disease model mice. Arctigenin was also shown to activate autophagy as evidenced by the upregulation of lipidated LC3, considered a marker for autophagosome formation. ARC-mediated activation of autophagy was postulated to be intermediated through the stimulation of AMP-activated protein kinase (AMPK) and mTOR signaling pathways.

Strength of evidence: Neuroprotective evidence is entirely preclinical (in vitro and animal models). No human clinical studies on arctiin or arctigenin for neurological disease have been published. Research in this area is exploratory.

5.6 Skin Disorders and Dermatology

Regulatory / Traditional endorsement: The ESCOP monograph for burdock root addresses therapeutic indications including seborrhoeic skin, eczema, furuncles, acne, and psoriasis. The European Medicines Agency (EMA) recommends the roots of Arctium lappa as adjunct therapy for seborrheic skin conditions.

Preclinical skin evidence: In an atopic dermatitis model, atopic dermatitis (AD) is a prevalent skin condition where the immune response plays a crucial role in its pathogenesis. Arctiin, a natural lignan, has been extensively investigated because of its anti-inflammatory, antioxidant, and anticancer properties as they may relate to AD. Burdock fruit and leaf extracts have been reported to inhibit tyrosinase in a biochemical assay and decrease melanin content in mouse melanoma cells; however, there are few studies in more advanced tissue models or in human subjects exploring this activity.

Strength of evidence: The use of burdock-based preparations for skin conditions has official monograph recognition from both ESCOP and EMA. Evidence for isolated arctiin specifically in human skin conditions is limited. Formal clinical trials for arctiin in dermatological indications are lacking.

5.7 Renal and Urinary Effects

Arctiin (120 mg/kg per os, once daily for 3 weeks) significantly improved cBSA-induced glomerulonephritis in a rat experimental model. The ESCOP monograph for burdock root also endorses use as an adjuvant in minor urinary tract complaints, by increasing the amount of urine to achieve flushing of the urinary tract. Evidence at the human clinical level for arctiin-specific renal effects is limited.

6. Body Systems and Health Areas Associated with Arctiin

Immune and Inflammatory System: Inhibition of NF-κB, COX-2, iNOS, and pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, PGE₂) in macrophages and epithelial cells; modulation of TLR4/MyD88 signaling.
Oncology: Cyclin D1 down-regulation in multiple human tumor cell lines; STAT3 phosphorylation inhibition; HIF-1α reduction in hepatocellular carcinoma models; anti-proliferative activity via retinoblastoma protein dephosphorylation.
Respiratory / Virology: Antiviral activity against influenza A (H1N1 and H9N2) via Nrf2/HO-1 and immune antibody pathways.
Metabolic / Endocrine: AMPK activation; GLUT4 translocation; adiponectin receptor 1 agonism; potential antidiabetic effects.
Nervous System: Neuroprotective effects in stroke and Alzheimer's disease animal models; autophagy regulation via AMPK/mTOR.
Skin / Integumentary: Anti-inflammatory effects relevant to eczema, atopic dermatitis, acne, psoriasis; possible tyrosinase inhibition.
Renal / Urinary: Diuretic effect attributed to the parent plant; experimental data in glomerulonephritis models for isolated arctiin.
Gastrointestinal: Prebiotic effects via associated inulin content in burdock; gut microbiota interaction in arctiin-to-arctigenin conversion.

7. Dosage Forms and Reported Dosages

Research on arctiin dosing is limited, and typical dosing is unavailable for both adults and children. Information on the standardization of burdock fruit is limited. Some clinical research utilized a product containing 1.2% burdock fruit extract standardized to 0.25% arctiin.

In preclinical animal studies, specific doses of arctiin have been reported. Some rats in a cancer model received a daily oral dose of 30 mg/kg of arctiin for three weeks. In an HCC rat model, arctiin was orally administered twice a week for 16 weeks at a dose of 30 mg/kg. For glomerulonephritis, a dose of 120 mg/kg per os once daily for 3 weeks has been reported.

In the toxicology study of arctigenin (the aglycone), three daily doses of arctigenin were tested at 12 mg/kg (1× minimal dose), 36 mg/kg (3× dose), and 120 mg/kg (10× dose), consisting of 28 days of feeding in three individual groups, plus a vehicle control group, followed by 28 weeks of recovery.

The clinical trial (NCT03703388) evaluating the safety and pharmacokinetics of pure arctigenin in healthy men did not have its dosage findings publicly available in the reviewed sources at the time of this writing.

Traditional decoctions and teas of Arctii Fructus (burdock fruit) are consumed in Asia, often using several grams of dried fruit material. Arctiin has been widely used in Asia, Europe, and North America for centuries in whole-plant preparations, making direct equivalence to isolated arctiin doses impossible to state based on available records.

8. Safety Considerations and Known Interactions

8.1 General Safety Profile

Although Arctii Fructus extract has shown no toxicity, arctigenin was toxic at a certain dose. Burdock is well-tolerated when used as a food, and historical use suggests few adverse effects. However, allergic reactions like contact dermatitis and anaphylaxis have been reported, albeit rarely.

Arctigenin belongs to the polyphenol class of compounds, which are generally found in fruits and vegetables and are regarded as safe and associated with diverse health-promoting effects. However, further comprehensive and systematic toxicity research for Arctii Fructus needs to be performed in order to ensure the safety of clinical application as a natural supplement.

8.2 Allergic Reactions

Burdock may cause an allergic reaction in people who are sensitive to the Asteraceae/Compositae family. People with fall seasonal allergies driven by ragweed or mugwort sensitization are at higher risk for cross-reactions with Asteraceae herbal extracts. Published case reports have documented allergic contact dermatitis due to burdock (Arctium lappa) upon topical application, as well as a reported case of anaphylaxis. Burdock is not to be used where there are known allergies to plants in the Asteraceae (daisy) family.

8.3 Pregnancy and Lactation

Pregnant women or women trying to conceive should avoid burdock. There is not enough reliable information to know if burdock is safe to use when pregnant or breast-feeding.

8.4 Drug Interactions

Theoretically, burdock may increase the risk of bleeding when taken in conjunction with antiplatelet medication; however, this has not been confirmed in human clinical trials. Burdock might interact with anticoagulant/antiplatelet drugs and herbs/supplements, potentially increasing the risk of bleeding.

The compound's estrogenic metabolites (produced via gut microbial transformation) present a theoretical concern for individuals using hormone-sensitive medications or those with hormone-sensitive conditions, though this has not been formally confirmed in human pharmacological studies.

8.5 Burdock Root Tea Contamination

Historical safety incidents with burdock are attributed to adulteration or contamination rather than to arctiin itself. Anticholinergic poisonings associated with commercial burdock root tea have been reported in the toxicological literature, likely resulting from contamination with belladonna alkaloids (from Atropa belladonna). This is not an intrinsic property of arctiin.

8.6 Precautions in TCM Context

In the TCM context, burdock is contraindicated in cases of diarrhoea and/or weakness (specifically, what is known in TCM as qi deficiency) and is not recommended for treating open sores.

8.7 Evidence Quality and Research Gaps

There is interest in using burdock for various purposes, including acne treatment, aging skin, atopic dermatitis, breast cancer, common cold symptoms, diabetes, diverticulitis, dry skin, gout, hepatitis, metabolic syndrome, urinary tract infections, and vaginitis, but the reliable evidence supporting its effectiveness is insufficient for most of these uses. Some preliminary research exists, but more robust studies are needed to establish its benefits.

The overall body of evidence reflects a compound with a well-established mechanistic rationale for anti-inflammatory, anticancer, and antiviral activities, supported by extensive in vitro and animal data, but with a comparatively sparse clinical trial record in humans. The alleviating effects of Arctii Fructus on chronic inflammation and ageing have been demonstrated by clinical studies, but large-scale, rigorous RCTs remain limited. The pharmacokinetic challenge of low oral bioavailability and extensive first-pass metabolism of arctigenin is a recognized obstacle to translating preclinical findings into clinical outcomes.

References

Health Conditions

Health conditions that Arctiin may help support.

No conditions available.

Body Systems

Body systems that Arctiin may help support.

No body systems available.